Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2017

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2017


  • Products Id :- GDHC513QD
  • |
  • Pages: 89
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2017

Summary

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals-Q1 2017", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q1 2017. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and an increase in deal values in Q1 2017 with 1,142 deals worth USD95.5 billion, as compared 1,165 worth USD91.4 billion in Q1 2016. On a quarter-on-quarter basis, the number of deals and deal values increased in Q1 2017, when compared to 1,082 deals worth USD84.3 billion in Q4 2016. The pharmaceutical and healthcare industry reported a decrease in upfront payments in licensing agreements with USD731m in Q1 2017, as compared USD1.3 billion in Q1 2016. On a quarter-on-quarter basis, the upfront payments reported a decrease in Q1 2017, when compared to USD1 billion in Q4 2016. Deals in oncology therapeutics market registered an increase with 421 deals in Q1 2017, compared to 356 deals in Q4 2016.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the five quarters.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2017 10

2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2017 10

2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2017 12

2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2017 13

2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017 14

2.4.1 Johnson & Johnson to Acquire Actelion for USD30 Billion 14

2.4.2 Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 15

2.4.3 Pfizer Raises USD4.2 Billion in Public Offering of Notes 15

2.4.4 Royalty Pharma Acquires Royalty Stream of Tysabri from Perrigo for USD2.85 Billion 16

2.4.5 Fresenius Raises USD2.7 Billion in Private Placement of Notes 16

3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2017 17

3.1.1 Top M&A Deals in Q1 2017 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2016-Q1 2017 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2017 20

3.2.1 Top Initial Public Offerings in Q1 2017 21

3.2.2 Top Secondary Offerings in Q1 2017 21

3.2.3 Top PIPE Deals in Q1 2017 22

3.2.4 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2016-Q1 2017 23

3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2017 24

3.3.1 Top Venture Financing Deals in Q1 2017 25

3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017 26

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2017 26

3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2016-Q1 2017 28

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q1 2016-Q1 2017 29

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016-Q1 2017 30

3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2017 31

3.4.1 Top Private Equity Deals in Q1 2017 32

3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2016-Q1 2017 33

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2017 34

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2017 34

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2016-Q1 2017 35

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2017 36

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2017 37

4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017 37

4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2017 38

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 39

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2016-Q1 2017 40

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (USD m), Q1 2016-Q1 2017 41

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 42

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2017 44

5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2017 44

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 45

5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2017 46

5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2017 46

5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2017 47

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (USD m), Q1 2016-Q1 2017 48

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (USD m), Q1 2016-Q1 2017 49

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), Q1 2016-Q1 2017 50

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (USD m), Q1 2016-Q1 2017 51

5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (USD m), Q1 2016-Q1 2017 52

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 54

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2017 54

6.1.1 Oncology-Deals of the Quarter 55

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2017 56

6.2.1 Central Nervous System-Deals of the Quarter 57

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2017 59

6.3.1 Infectious Disease-Deals of the Quarter 60

6.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2017 61

6.4.1 Immunology-Deals of the Quarter 62

6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2017 63

6.5.1 Metabolic Disorders-Deals of the Quarter 64

6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2017 65

6.6.1 Cardiovascular-Deals of the Quarter 66

6.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2017 67

6.7.1 Gastrointestinal-Deals of the Quarter 68

6.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2017 70

6.8.1 Ophthalmology-Deals of the Quarter 71

6.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2017 72

6.9.1 Respiratory-Deals of the Quarter 73

6.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2017 74

6.10.1 Dermatology-Deals of the Quarter 75

7 Deal Summary by Geography 77

7.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2017 77

7.1.1 North America-Deals of the Quarter 78

7.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2017 79

7.2.1 Europe-Deals of the Quarter 80

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2017 81

7.3.1 Asia-Pacific-Deals of the Quarter 82

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2017 83

7.4.1 Rest of the World-Deals of the Quarter 84

8 Pharmaceuticals & Healthcare, Global, Top Advisors 85

8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q1 2016-Q1 2017 85

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Q1 2016-Q1 2017 86

9 Further Information 87

9.1 Methodology 87

9.2 About GlobalData 88

9.3 Contact Us 88

9.4 Disclosure information 88

9.5 Disclaimer 89

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), Q1 2017 12

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), Q1 2017 13

Figure 4: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q1 2016-Q1 2017 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (USD m), , Q1 2016-Q1 2017 23

Figure 8: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 24

Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%), Q1 2017 26

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Deal Values (%), Q1 2017 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q1 2016-Q1 2017 28

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 29

Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 31

Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, Q1 2016-Q1 2017 33

Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 34

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 35

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Values (USD m), Q1 2016-Q1 2017 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), Q1 2016-Q1 2017 39

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016-Q1 2017 40

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016-Q1 2017 41

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Values (USD m), Q1 2016-Q1 2017 42

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 44

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 45

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 48

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 49

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals, Q1 2016-Q1 2017 50

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Deal Values (USD m), Q1 2016-Q1 2017 51

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 52

Figure 29: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 54

Figure 30: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 56

Figure 31: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 59

Figure 32: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 61

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 63

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 65

Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 67

Figure 36: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 70

Figure 37: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 72

Figure 38: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 74

Figure 39: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 77

Figure 40: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 79

Figure 41: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 81

Figure 42: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 83

Figure 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 85

Figure 44: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 86

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deal Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 11

Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2017 13

Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2017 14

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 17

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q1 2017 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, , Q1 2016-Q1 2017 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q1 2017 21

Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q1 2017 21

Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q1 2017 22

Table 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 23

Table 12: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 24

Table 13: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q1 2017 25

Table 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2017 27

Table 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 28

Table 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 29

Table 17: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q1 2016-Q1 2017 30

Table 18: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 31

Table 19: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q1 2017 32

Table 20: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 33

Table 21: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 34

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 35

Table 23: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 36

Table 24: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payments and Deal Values (USD m), Q1 2017 37

Table 25: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2017 37

Table 26: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2017 38

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (USD m), Q1 2016-Q1 2017 39

Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016-Q1 2017 41

Table 29: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (USD m), Q1 2016-Q1 2017 43

Table 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 44

Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payments and Deal Values (USD m), Q1 2016-Q1 2017 45

Table 32: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2017 46

Table 33: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2017 46

Table 34: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2017 47

Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 48

Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (USD m), Q1 2016-Q1 2017 49

Table 37: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q1 2016-Q1 2017 51

Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Values (USD m), Q1 2016-Q1 2017 53

Table 39: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 55

Table 40: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 57

Table 41: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 60

Table 42: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 62

Table 43: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 64

Table 44: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 66

Table 45: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 68

Table 46: Pharmaceuticals & Healthcare, Global, Ophthalmology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 71

Table 47: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 73

Table 48: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 75

Table 49: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 78

Table 50: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 80

Table 51: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 82

Table 52: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 84

Table 53: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 85

Table 54: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), Q1 2016-Q1 2017 86

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

select a license

Single User License
USD 1500 INR 100395
Site License
USD 3000 INR 200790
Corporate User License
USD 4500 INR 301185

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com